Observational Study
Copyright ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Pharmacol Ther. May 6, 2017; 8(2): 127-130
Published online May 6, 2017. doi: 10.4292/wjgpt.v8.i2.127
Correlation of rapid point-of-care vs send-out fecal calprotectin monitoring in pediatric inflammatory bowel disease
Alexis Rodriguez, Lauren Yokomizo, Megan Christofferson, Danielle Barnes, Nasim Khavari, K T Park
Alexis Rodriguez, Lauren Yokomizo, Megan Christofferson, Danielle Barnes, Nasim Khavari, K T Park, Stanford University School of Medicine, Stanford University, Palo Alto, CA 94304, United States
Alexis Rodriguez, Megan Christofferson, Danielle Barnes, Nasim Khavari, K T Park, Division of Gastroenterology, Department of Pediatrics, Stanford University, Palo Alto, CA 94304, United States
Author contributions: Rodriguez A and Yokomizo L contributed equally to this work; Park KT conceptualized the study; Rodriguez A, Yokomizo L, Christofferson M, Barnes D, Khavari N and Park KT participated in sample analysis and assisted in the logistics of the study; Rodriguez A, Yokomizo L and Park KT participated in the statistical analysis, wrote the manuscript and approved the final manuscript draft; Christofferson M, Barnes D and Khavari N edited and approved the final manuscript draft.
Institutional review board statement: This study had IRB approval from Stanford University.
Informed consent statement: Informed consent and assent forms were obtained prior to patient enrollment.
Conflict-of-interest statement: KT Park has served as consultant for Inova Diagnostics and received research support from BUHL MANN Laboratories.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: K T Park, MD, MS, Division of Gastroenterology, Department of Pediatrics, Stanford University, 750 Welch Road, Ste 116, Stanford, Palo Alto, CA 94304, United States. ktpark@stanford.edu
Telephone: +1-650-7235070 Fax: +1-650-4985608
Received: May 25, 2016
Peer-review started: May 27, 2016
First decision: July 22, 2016
Revised: December 21, 2016
Accepted: January 16, 2017
Article in press: January 18, 2017
Published online: May 6, 2017
Processing time: 344 Days and 0.1 Hours
Core Tip

Core tip: Quantitative fecal calprotectin (FC) measurements, particularly in children affected by inflammatory bowel disease (IBD), is an important element of disease monitoring in a patient population vulnerable to repeated endoscopic confirmation of mucosal healing. In the United States, rapid FC assays are not yet Food and Drug Administration approved, and send-out FC assays require processing delay, preventing point-of-care usefulness. The significance of our findings in this study reiterate the clinical utility of the point-of-care FC testing in children with IBD, who are at-risk for subclinical mucosal-level inflammation. Our study confirms good correlation between the send-out and rapid point-of-care FC tests at the clinically-meaningful target range (≤ 250 μg/g) associated with endoscopic remission.